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Chronic active antibody mediated rejection
Circulating immune cells
A B S T R A C T
Chronic-active antibody mediated rejection (c-aABMR) contributes signiﬁcantly to late renal allograft failure.
The antibodies directed against donor-derived antigens, e.g. anti-HLA antibodies, cause inﬂammation at the
level of the microvascular endothelium. This is characterized by signs of local activation of the complement
system and accumulation of immune cells within the capillaries. Non-invasive biomarkers of c-aABMR are
currently not available but could be valuable for early detection. We therefore analyzed the activation proﬁles of
circulating T and B cells, NK cells and monocytes in the peripheral blood of 25 kidney transplant recipients with
c-aABMR and compared them to 25 matched recipients to evaluate whether they could serve as a potential
biomarker.
No signiﬁcant diﬀerences were found in the total percentage and distribution of NK cells, B cells and T cells
between the c-aABMRpos and c-aABMRneg cases. There was however a higher percentage of monocytes present
in c-aABMRpos cases (p < .05). Additionally, diﬀerences were found in activation status of circulating mono-
cytes, NK cells and γδ T cells, mainly concerning the activation marker CD16. Although statistically signiﬁcant,
these diﬀerences were not suﬃcient for use as a biomarker of c-aABMR.
1. Introduction
Chronic-active antibody-mediated rejection (c-aABMR) is a sig-
niﬁcant long-term complication after kidney transplantation. It causes
severe graft injury and c-aABMR is now recognized as one of the major
barriers for long term renal allograft survival [1–4].
The histomorphological lesions of c-aABMR develop over time and
are associated with recurrent and episodic endothelial activation
caused by antibodies recognizing donor-speciﬁc antigens on the renal
endothelial cells. The subsequent inﬂammation is speciﬁcally found at
the level of the microcirculation [4–7]. Pre-transplant donor speciﬁc
antibodies against HLA (DSA) and de novo DSA, which develop after
transplantation, play an important role in the development of c-aABMR
[8]. However, in a substantial number of cases DSA cannot be detected
in the serum at time of diagnosis [9–12].
The antibodies on the endothelial cells are targeted by leukocytes
bearing Fc-γ receptors. In turn, the Fc-receptor-mediated activated cells
can produce pro-inﬂammatory cytokines such as interferon-gamma
(IFN-γ) and upregulated expression of levels IFN-γ in the graft and
serum have been described during ABMR [13,14]. In combination with
a variable degree of local complement activation, the activation of
immune cells results in endothelial injury. The persistent endothelial
injury leads to structural histomorphological changes of the glomeruli
with loss of fenestration and duplication/multilamination of the base-
ment membranes; more speciﬁcally known as transplant glomerulo-
pathy (TG) [6,15–18].
All circulating immune cells bearing Fc-receptors can potentially be
activated by.
endothelial cells in c-aABMR, however, in particular innate immune
cells such as monocytes and NK cells are typically present in the glo-
merular and peritubular capillaries [14,19].
In addition, speciﬁc T cell subsets have been recognized as poten-
tially important immune modulators in rejection. For instance, cyto-
megalovirus-responsive (CMV) γδ T cells are possible eﬀector cells in
antibody mediated rejection and Baeten et al., identiﬁed increased
numbers of CD8+CD28− eﬀector lymphocytes in patients with
chronic graft rejection [20,21].
Non-invasive biomarkers of c-aABMR are currently not available but
could be valuable for early detection and subsequent treatment.
Whether the continuous activation of immune cells can be detected in
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the circulation of patients with c-aABMR and may serve as a potential
biomarker, is unknown. In this study we investigated monocytes, NK
cells, B cells and T cells with their subsets in combination with a variety
of activation markers expressed on these cells (HLA-DR, CD25, CD38
and CD71) in relation to c-aABMR.
2. Patients and methods
2.1. Study population
This case-control study included 25 cases of kidney transplant re-
cipients diagnosed with chronic active antibody-mediated rejection (c-
aABMRpos) and 25 matched controls (c-aABMRneg). Blood samples
were collected at time of diagnosis between June 2016 and November
2017 at the Erasmus University Medical Center (Rotterdam, The
Netherlands).
The c-aABMRneg cases were matched for age, gender and time after
transplantation and had a for-cause renal biopsy which showed no
evidence of rejection. All renal biopsies were for-cause and evaluated
by an experienced renal pathologist based on the then current Banﬀ
classiﬁcation [22,23].
Kidney transplant recipients gave written informed consent and the
study was approved by the Medical Ethical Committee of the Erasmus
MC (MEC-2017-115). The study was conducted in accordance with the
Declaration of Helsinki and the Declaration of Istanbul.
2.2. Data collection and isolation of serum and peripheral blood
mononuclear cells (PBMCs)
Demographic and baseline transplantation characteristics were
collected for all patients at time of for-cause biopsy. Blood was drawn
from the kidney transplant recipients prior to the for-cause biopsy.
Peripheral blood mononuclear cells (PBMCs) were isolated from he-
parinized blood samples by using Ficoll-Paque Plus (GE healthcare,
Uppsala, Sweden) [24]. The isolated PBMCs were washed, frozen at
10×106/vial in RPMI-1640 with Glutamax (GibcoBRL) supplemented
with 100 IU/mL penicillin/streptomycin and 10% heat-inactivated
pooled human serum and 10% dimethyl sulphoxide (Sigma Aldrich,
Darmstadt, Germany) in liquid nitrogen until further use. One vial of
PBMCs was thawed in RPMI-1640 (Gibco BRL) containing penicillin/
streptomycin and DNase (Sigma Aldrich), washed, the cells counted and
viability assessed using trypan blue.
Serum was collected upon centrifuging the coagulation tube for
10min at 3000 rpm and stored at 1mL/ampoule at -80 °C for de-
termination of DSA.
2.3. Characterization PBMCs by ﬂow cytometry
PBMCs were characterized for proportions of diﬀerent populations
as well as their activation state using ﬂow cytometry. The activation
state was evaluated by analyzing frequencies and median ﬂuorescence
intensity of human leukocyte antigen-DR (HLA-DR)-, CD25-, CD38- or
CD71-expressing cells. HLA-DR is expressed on B cells, monocytes, ac-
tivated T cells and activated NK cells. CD25 is the α-chain of the IL-2
receptor and its expression is also increased upon activation of T cells
and B cells. CD38 is a glycoprotein involved in cell adhesion, signal
transduction and calcium signaling and expressed on T cells, B cells,
monocytes and NK cells. CD71 is the transferrin receptor involved in
iron transport from transferrin into cells by endocytosis and its ex-
pression is increased upon activation on T and B cells.
PBMCs were divided over 5 diﬀerent polystyrene FACS tubes
(Becton Dickinson, BD; Erembodegem, Belgium) and stained using
diﬀerent antibody panels. Below a brief description of the panels is
given. Detailed information with respect to the diﬀerent antibodies
within each panel is provided within Supplemental Table 1.
In panel 1, percentages of monocyte subsets and NK cells are de-
termined as well as their activation state. Using the combination of
CD14 and CD16, classical (CD14++CD16−), intermediate
(CD14+CD16+) and non-classical (CD14+CD16++) monocytes were
identiﬁed within PBMCs as described by Ziegler-Heitbrock et al. [25].
The NK cells are identiﬁed as negative for CD3 and CD19 and positive
for CD56 either co-expressing CD16 or not [26].
In panel 2, percentages of B cell subsets are determined as described
by Kaminski et al. as well as their activation state [27]. B cells are
Table 1
Clinical and demographic characteristics (at time of for cause biopsy).
Total (50) c-aABMRpos cases (n=25) c-aABMRneg cases (n= 25) p-Value
Women, n (%) 15 (30) 8 (32) 7 (28) 0.76
Age of patient, yr, median (IQR) 52 (39–66) 53 (44–66) 51 (35–68) 0.85
Living donor, n (%) 41 (82) 21 (84) 20 (80) 0.71
Prior kidney transplant, n (%) 10 (20) 6 (24) 4 (16) 0.48
Donor age, yr, median (IQR) 51 (43–61) 52 (46–62) 48 (40–48) 0.21
PRA current, median (IQR) 0 (0–5) 2 (0–8) 0 (0–0) 0.17
Donor Speciﬁc Antibodies, n (%) – 12 (48) –
HLA mismatch, median (IQR) 3 (2–4) 3 (2–5) 3 (1–4) 0.85
Maintenance immunosuppression, n (%)
Tacrolimus/cyclosporine 47 (94) 23 (92) 24 (96) 0.55
mTOR inhibitor 1 (2) 0 (0) 1 (4) 0.31
Steroids 24 (48) 11 (44) 13 (52) 0.57
Mycophenolate mofetil 43 (86) 24 (96) 19 (76) 0.04
Other 3 (6) 0 (0) 3 (12) 0.08
Maintenance immunosuppression, n (%)
Triple immunosuppression 18 (36) 8 (32) 10 (40) 0.56
Double immunosuppression 32 (64) 17 (68) 15 (60)
Primary kidney disease, n (%)
Diabetic nephropathy 9 (18) 5 (20) 4 (16) 0.36
Hypertensive nephropathy 5 (10) 1 (4) 4 (16)
Polycystic kidney disease 7 (14) 5 (20) 2 (8)
Primary glomerulopathy 13 (26) 5 (20) 8 (32)
Other 15 (30) 9 (36) 6 (24)
Unknown 1 (2) 0 (0) 1 (4)
Time to for cause biopsy, yr, median (IQR) 4.2 (3.0–10.6) 4.2 (2.9–11.6) 4.1 (3.0–11.0) 0.92
Graft function (ml/min), median (IQR) 33 (28–44) 33 (27–43) 36 (29–49) 0.55
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identiﬁed as CD19+ and using the combination of IgD and CD27, naïve
B cells (CD27−IgD+) can be dissected from non-class switched
(CD27+IgD+), class-switched (CD27+IgD−) and double negative (DN,
CD27−IgD−) memory B cells. Plasma blast can be identiﬁed within the
circulation by combining expression of CD27 and CD38
(CD27++CD38++) and transitional B cells by high expression of both
CD24 as well as CD38.
In panel 3 we evaluate percentages of T cells expressing Vδ1 and
Vδ2 T cell receptor (TCR) as well as their activation state. As these cells
have been implicated in antibody-mediated rejection in kidney trans-
plant recipients and also can express CD16, we also determined per-
centages and median ﬂuorescence intensity (MFI) of CD16 (Fc gamma
III receptor) [21]. Gamma delta T cells are identiﬁed as CD3+ and
positive for either Vδ1 or Vδ2. Within the circulation predominantly
Vδ2+Vδ1 γδ− T cells are observed [28].
In panel 4, we measure frequencies of CD4+ and CD8+ T cells
(expressing the alpha beta TCR) as well as their activation state and in
panel 5, we characterize the diﬀerent CD4+ and CD8+ T cell subsets in
more detail by evaluating their diﬀerentiation status. The diﬀerentia-
tion status was based on the study by Sallusto et al., as described in
detail previously by Betjes et al. [29,30]. Brieﬂy, expression of CD45RO
(marker for memory T cells) and CCR7 (a chemokine receptor which
facilitates T cells to home to secondary lymphoid organs) was used to
determine naive (CD45RO−CCR7+) and diﬀerent memory T-cell po-
pulations. Diﬀerent memory T-cell subsets were deﬁned as central
memory (CM) T cells (CD45RO+CCR7+ T cells), eﬀector memory (EM)
T cells (CD45RO+CCR7− T cells) and EMRA T cells (highly diﬀer-
entiated CD45RA+CCR7− eﬀector memory T cells). Furthermore, we
have determined frequencies of more diﬀerentiated T cells based on the
loss of the co-stimulatory molecule CD28 on the cell surface of these
cells.
Upon staining the cells for 30min at room temperature with the
diﬀerent antibody cocktails, the samples were washed using BD
FACSﬂow (BD), measured on the FACSCanto II (BD; 3 laser, 8 color
conﬁguration 4:2:2) and analyzed using Kaluza software version 1.3
(Beckman Coulter BV., Woerden, The Netherlands) generating a linear
value for median ﬂuorescence intensity of the diﬀerent activation
markers. Multiplying this value by 256 makes it comparable to those
obtained by other ﬂow cytometry analysis software. To be able to dis-
sect the diﬀerent populations of cells and analyze their activation state,
we aimed to acquire at least 50.000 PBMCs. A typical example of ﬂow
cytometric analyses and gating strategy for the diﬀerent cells is given in
Supplemental Fig. 1A–D and in Supplemental Fig. 2A–F the gating of
the diﬀerent activation markers for particular cell population is given.
Fluorescence minus one (FMO) controls were used to determine posi-
tivity for each activation marker. Data of all activation markers are
depicted in Supplemental Tables 2–6.
2.4. Statistical analysis
Normally distributed data are expressed as mean +/− SD, non-
normally distributed data as median (IQR). The total cell populations
and their distribution were expressed as median percentages (IQR). The
activation state was evaluated by analyzing frequencies of cells positive
for an activation marker and the median ﬂuorescence intensity (MFI) of
the positive fraction as a marker for expression level of the activation
marker. All frequencies are expressed as median percentages (IQR) and
the MFI's as median values (IQR).
The statistical analyses were performed using Graphpad Prism 6 and
SPSS software version 24. Statistical signiﬁcance was calculated by
Fisher's exact test, Mann-Whitney-U test and two-way ANOVA. A p-
value of< 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Baseline characteristics
A detailed description of demographics and clinical characteristics
of the study population is given in Table 1. The majority of patients
were male (70%) with a median age of 52 and transplanted with a
kidney from a living donor (82%). Most patients received tacrolimus
and mycophenolate mofetil (94% and 86%) as their im-
munosuppressive therapy. The biopsies were taken at a median of
4.2 years after transplantation (c-aABMRpos 4.2 yrs. versus c-
aABMRneg 4.1 yrs.; p= .92). The majority of c-aABMRneg cases had
signs of chronic damage attributed to CNI toxicity in their biopsy.
The CMV serostatus of the patients is of interest as CMV primo in-
fection and latency are associated with increased numbers of diﬀer-
entiated CD4+ and CD8+ T cells [31]. However, no diﬀerences were
found in CMV mismatch (p= .72). A total of 10 patients had a CMV
mismatch in which the donor was CMV positive and the acceptor CMV
negative (n=6 for cases, n=4 for controls). Of those 10 mismatch
patients, three cases and two controls had undergone seroconversion
after transplantation.
3.2. Monocytes and NK cells
The total percentage of monocytes was signiﬁcantly higher in the c-
aABMRpos cases (19.5%; 10.8–30.5%) compared to the c-aABMRneg
cases (14.4%; 8.2–21.4%) (p < .05) even though the distribution of
classical (CD14++CD16−), intermediate (CD14+CD16+) and non-
Fig. 1. a. Total percentage of monocytes in c-aABMRpos and c-aABMRneg
cases; b. Distribution of monocyte subsets; c. CD38 expression on monocytes.
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classical (CD14+CD16++) monocytes was similar. However, the c-
aABMRpos cases showed a signiﬁcantly higher percentage of mono-
cytes expressing the activation marker CD38 compared to the c-
aABMRneg cases (c-aABMRpos 99.3% versus c-aABMRneg 98.4%;
p= .04) (Fig. 1a–c). Upon analysis DSA presence in the c-aABMRpos
cases was not associated with the signiﬁcant diﬀerences.
Similar to the data on monocytes, the percentage of NK cells in c-
aABMR cases tended to be higher (17.5%; 6.8–22.1%) compared to the
c-aABMRneg cases (10.7%; 3.4–19.6%) although statistical signiﬁcance
was not reached (p= .14) and NK cell subsets distribution was similar
(p= .51). However, NK cells of c-aABMRpos cases showed a sig-
niﬁcantly higher expression of CD16 (Fcγ III receptor) and CD38
(p < .01 and p= .02) based on MFI. The median CD16 MFI of NK cells
of c-aABMRpos cases was 56,965 (33734–68,403) and for NK cells of c-
aABMRneg cases 34,345 (16878–40,092). For CD38 MFI these values
were 6403 (5206–7336) and 5079 (4040–6240), respectively
(Fig. 2a–d). The signiﬁcant changes found in the expression proﬁle of
NK cells showed no association with DSA presence in the c-aABMRpos
cases.
3.3. B cells
The overall percentage of B cells was similar for c-aABMRpos cases
and c-aABMRneg cases (p= .68; c-aABMRpos 2.7% (1.4–7.0%); c-
aABMRneg 4.2% (1.6–5.5%)), as was the distribution of B cell subsets
(p= .95). Of interest was the tendency for higher expression of the
activation marker HLA-DR on B cells in patients with c-aABMR
(p= .09) (Fig. 3a–c). The median MFI of HLA-DR for B cells of c-
aABMRpos cases was 2202 (1967–2728) and for c-aABMRneg cases
2132 (1750-2698).
3.4. T cells
The total percentage of T cells (CD3+ cells) was 69.9%
(58.5–79.4%) for the c-aABMRpos cases and 68.1% (55.7–80.3%) for
the c-aABMRneg cases which did not diﬀer signiﬁcantly (p= .65).
Neither was there a diﬀerence in frequencies of CD4+ (p= .79) and
CD8+ T cells (p= .77) (Fig. 4a–b). Furthermore, no signiﬁcant diﬀer-
ence in expression of activation markers (HLA-DR, CD38, CD71 and
CD25) were found for CD3+, CD4+ and CD8+ T cells.
Additionally, we analyzed in detail the diﬀerentiation status of the
CD4+ and CD8+ T cell subsets. However, similar percentages were
found for naïve, CM, EM, EMRA and CD28null subsets within CD4+
and CD8+ T cells in c-aABMRpos and c-aABMRneg cases (Fig. 4c–d).
3.5. γδ T cells
The frequency of γδ T cells did not diﬀer signiﬁcantly between c-
aABMRpos and c-aABMRneg cases (p= .88; c-aABMRpos 2.4%
(1.3–4.7%); c-aABMRneg 2.2% (1.5–5.8%)). The ratio of Vδ1 and Vδ2
subsets also did not diﬀer signiﬁcantly when comparing cases to con-
trols (p= .40) (Fig. 5a–b). Upon evaluation of the activation markers,
the expression of HLA-DR was signiﬁcantly higher in the c-aABMRneg
cases (p= .02; MFI c-aABMRpos 637 (590–708); MFI c-aABMRneg 712
(641–824)), as well as the expression of CD16 (p= .02; MFI c-
aABMRpos 837 (684–1280); MFI c-aABMRneg 1277 (955–2381))
(Fig. 5c–d).
4. Discussion
Chronic active antibody mediated rejection is an important cause of
late renal allograft failure [1,2]. With little knowledge on prevention,
the underlying pathomechanisms as well as the absence of an eﬀective
treatment, c-aABMR remains a clinical challenge [32]. Unfortunately,
Fig. 2. a. Total percentage of NK cells in c-aABMRpos and c-aABMRneg cases; b. Distribution of NK cell subsets; c. CD16 expression on NK cells; d. CD38 expression
on NK cells.
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until present, the gold standard for the diagnosis of c-aABMR remains
renal biopsy due to the absence of adequate biomarkers. In this study
we provide the ﬁrst in-depth analysis into the diﬀerent leukocyte sub-
sets and their activation markers in the peripheral blood of patients
with c-aABMR in comparison to matched controls.
We found similar distribution in c-aABMRpos cases and c-
aABMRneg cases for NK cells, B cells, T cells and their speciﬁc subsets.
However, subtle diﬀerences were present in the overall percentage of
monocytes and expression of activation markers with generally a more
activated proﬁle of circulating monocytes and NK cells in patients with
c-aABMR.
Monocyte subset distribution has been implicated as a potential
biomarker for acute rejection in renal transplant recipients [19], but no
data are present on the relation with development of either acute or
chronic ABMR. The results of this study did not ﬁnd diﬀerences in
frequency of classical, intermediate and non-classical monocytes but
did show a higher overall percentage of monocytes in patients with c-
aABMR. CD38 expression was signiﬁcantly higher in cases of c-aABMR
but this seemed to be related to several unexplained outliers in the c-
aABMRneg group and MFI of the CD38 expression was comparable in
both groups.
Similar to the monocytes, the median percentage of NK cells tended
to be higher in the c-aABMR cases with increased expression of the
activation markers CD16 and CD38. It has been hypothesized by several
groups that eﬀector mechanisms other than complement can be acti-
vated through DSA [33,34]. An ABMR model was proposed in which
the contribution of NK cells at endothelial level is mediated by CD16
engagement to DSA [35]. Damage is inﬂicted through antibody-de-
pendent cell-mediated cytotoxicity (ADCC) mediated by Fc receptors on
the cell surface that bind IgG antibodies (CD16) [14,21,36]. The in-
teraction through the low aﬃnity FcR type III (CD16) is crucial as it
stimulates regulation of proliferation, migration of other leukocytes and
endothelial cytotoxicity by releasing granule content and pro-in-
ﬂammatory CD16-inducible cytokines. The increased expression of
CD16 would conﬁrm this possible underlying pathophysiological me-
chanism leading to c-aABMR [13,35,37,38].
Activated T cells may also be a source of IFN-γ production in c-
aABMR but we found no diﬀerences in the percentage of circulating T
cells, diﬀerentiation and activation status. Therefore, in line with pre-
viously published models our data are not in support of a major pa-
thophysiological role for T cells in c-aABMR [13,39,40].
Of interest in this respect is the observation that a speciﬁc subset of
T cells namely Vδ2neg γδ T cells also express CD16 and their ADCC
function is triggered after interaction with cell bound antibodies. These
cells are suspected to play a role in acute ABMR as γδ T cells were found
in peritubular capillaries during ABMR and their peripheral blood ex-
pansion may be considered a poor prognostic factor for allograft func-
tion [21]. Of interest, the number of these cells in the peripheral blood
is related to the CMV serostatus as CMV infection causes activation and
expansion of CD16+ γδ T cells.
However, the data from this study do not show signiﬁcant diﬀer-
ences between the number and subset distribution of γδ T cells between
c-aABMRpos and c-aABMRneg cases. In addition, no diﬀerence with
respect to frequency of CMV-seropositive kidney transplant recipients
was observed between the two groups Remarkable was the signiﬁcantly
lower expression of CD16 and HLA-DR in the c-aABMRneg cases. As
previously postulated by van den Bosch et al., it is possible that these
cells have migrated to the inﬂamed graft rather than remained in the
circulation [19].
Furthermore, we found no diﬀerences in the percentage of B cells,
their diﬀerentiation status and activation markers. These ﬁndings are
similar to those of Hidalgo et al. who established a DSA selective
transcript algorithm and found no B cell transcripts in renal biopsies
with ABMR [14]. Previously, it was demonstrated that the expression of
B cell associated transcripts (BAT) are features of scarring and injury.
BAT are associated with time post-transplantation and have no relation
to ABMR or DSA [41].
Until present, the majority of studies have focused on the histolo-
gical characterization and transcriptomes of speciﬁc cells in early re-
jection. Although there are several studies that have analyzed periph-
eral blood in search of potential predictive markers, most have
investigated pre-transplant samples rather than samples at time of re-
jection [19,42,43]. This is the ﬁrst study to, in detail, describe the
circulating immune cells and their activation and diﬀerentiation mar-
kers at time of c-aABMR diagnosis. In spite of the limited numbers of
included patients, this study contains a clearly deﬁned group of c-
aABMR patients with a time-, age- and gender-matched control group.
4.1. Conclusion
In conclusion, our current results demonstrate diﬀerences in the
numbers and activation status of circulating monocytes, NK cells and γδ
T cells in the peripheral blood of c-aABMRpos and c-aABMRneg pa-
tients. Taken together, the data are consistent with activation of cells
that bear the Fc receptor CD16 and ﬁt within the hypothesis that in-
teraction with antibodies on renal endothelial cells leave a footprint in
the circulating CD16pos immune cell populations. However, these are
subtle diﬀerences and are not ﬁt to serve as biomarkers. Nevertheless,
the data are of interest and indicate an important role for CD16 positive
innate immune cells in the pathogenesis of c-aABMR.
Fig. 3. a. Total percentage of B cells in c-aABMRpos and c-aABMRneg cases; b.
Distribution of B cell subsets; c. HLA-DR expression on B cells.
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Fig. 4. a. Total percentage of CD3+ T cells in c-aABMRpos and c-aABMRneg cases; b. Distribution of CD4+ and CD8+ T cells; c. Distribution of CD4+ T cell subsets;
d. Distribution of CD8+ T cell subsets.
Fig. 5. a. Total percentage of γδ T cells in c-aABMRpos and c-aABMRneg cases b. Distribution of γδ T cell subsets in CD3+ T cells; c. HLA-DR expression on γδ T cells;
d. CD16 expression on γδ T cells.
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